Clinical Trial

68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Trial Details
NCT Number NCT06740240
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Tumor
Enrollment 30 participants
Start Date 2024-03-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-18